Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.
about
Strategies to improve the immunosuppressive properties of human mesenchymal stem cellsCortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.Mechanism underlying defective interferon gamma-induced IDO expression in non-obese diabetic mouse fibroblastsA powerful yeast-based screening assay for the identification of inhibitors of indoleamine 2,3-dioxygenase.Inhibitors of indoleamine 2,3-dioxygenase: a review of novel patented lead compounds.Microarray analysis of gene expression in West Nile virus-infected human retinal pigment epitheliumDysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease.Determination of l-tryptophan and l-kynurenine in Human Serum by using LC-MS after Derivatization with (R)-DBD-PyNCS.Changes in plasma kynurenic acid concentration in septic shock patients undergoing continuous veno-venous haemofiltration.Effects of Kynurenine Pathway Inhibition on NAD Metabolism and Cell Viability in Human Primary Astrocytes and Neurons.Effect of ex vivo culture conditions on immunosuppression by human mesenchymal stem cells.The cystine/glutamate antiporter regulates indoleamine 2,3-dioxygenase protein levels and enzymatic activity in human dendritic cells.Treatment with granulocyte-macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock.Redox control of indoleamine 2,3-dioxygenase expression and activity in human monocyte-derived dendritic cells is independent of changes in oxygen tension.Enhanced Immunosuppressive Properties of Human Mesenchymal Stem Cells Primed by Interferon-γ.
P2860
Q26786626-7A0EE7FA-5DB1-4A64-A882-1D981332E601Q33707711-A2EB0CBA-B2BB-4FD7-8D5E-33984DC47D80Q34291222-6E5B2243-4F12-4405-A22A-89154845F43EQ34335219-46FBC269-115B-471E-95D2-FC31B0985FB3Q34616168-135C145B-76B5-4268-9301-A4F9F75A1727Q35883310-3CD60214-DC10-4500-874D-CDF73E617077Q37040974-9586E49F-AF3E-4B4C-834A-58D9A1612BECQ37059674-B6B0C1FC-3D48-44A7-8371-FFED5BBB7CD1Q37592913-7E56D6BC-F0DB-40FB-BEEF-0CA6BEC310F5Q38728529-1622016A-B0E0-4B24-B1BA-2FB36FEFE83BQ42182025-98F2DE63-2E6A-4D5D-8F85-B311BBCC8DCEQ42408190-3CB7A198-DDF3-4828-B781-C3438EED7670Q43230804-BFAA690E-39AE-4D23-A9EF-DB80E5039D3EQ44995189-611CEE9F-689A-4F60-AA54-735DF8493637Q49795920-490A7AFE-2DC3-497D-B2EF-4A06A43D5E49
P2860
Manipulation of indoleamine 2,3 dioxygenase; a novel therapeutic target for treatment of diseases.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@en
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@nl
type
label
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@en
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@nl
prefLabel
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@en
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@nl
P2860
P1476
Manipulation of indoleamine 2, ...... get for treatment of diseases.
@en
P2093
P2860
P304
P356
10.1517/14728220903018940
P407
P577
2009-08-01T00:00:00Z